In trading on Wednesday, shares of Universal Stainless & Alloy Products, Inc. (USAP - Get Report) entered into oversold territory, changing hands as low as $16.4201 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In the case of Universal Stainless & Alloy Products, Inc., the RSI reading has hit 29.2 — by comparison, the universe of metals and mining stocks covered by Metals Channel currently has an average RSI of 37.3, the RSI of Spot Gold is at 32.7, and the RSI of Spot Silver is presently 32.9. A bullish investor could look at USAP's 29.2 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), USAP's low point in its 52 week range is $16.4201 per share, with $32.54 as the 52 week high point — that compares with a last trade of $16.55. Universal Stainless & Alloy Products, Inc. shares are currently trading off about 4.6% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
What Every Investor Needs to Know: Cramer's 'Mad Money' Recap (Monday 6/24/19)
Jim Cramer explains the ins and outs of essential economic and investing lessons that every stock investor needs to know.
The Weak Dollar Is the Main Force in the Market Right Now
Gold continues to run higher as the dollar continues to collapse.
Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
Stocks end little changed Monday as investors look to the upcoming G-20 summit for a breakthrough in talks between the world's two largest economies.
Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
About 6 million women suffer from hypoactive sexual desire disorder, which Palatin's Vyleesi is designed to treat.